Biodegradable tissue replacement implant and its use

An implant and tissue technology, applied in tissue regeneration, medical science, prosthesis, etc., can solve problems such as methods that have not yet provided functional verification

Pending Publication Date: 2021-08-06
UNITED STATES OF AMERICA
View PDF69 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previous methods have not provided functional validation in multiple patients (Kamao et al., Stem Cell Reports 2, 205-218 (2014))

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biodegradable tissue replacement implant and its use
  • Biodegradable tissue replacement implant and its use
  • Biodegradable tissue replacement implant and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0261] Materials and methods

[0262] Research and Clinical Grade iPSC Derivation, Maintenance and RPE Differentiation: Reporter iPSC Lines Expressing GFP Under the Control of a Tyrosinase Enhancer and Constitutive RFP have been previously published (Maruotti et al., Proc Natl Acad Sci U SA112, 10950-10955(2015)), and for optimizing research-grade differentiation protocols. iPSCs were cultured on MEFs for 4 days before being used for differentiation. To prepare cell aggregates, iPSCs were treated with collagenase for 20 min. After aspirating collagenase, NEIM (DMEM / F12, KOSR, supplement N2, B27, LDN-193189 10uM, SB431452 10nM, CKI-7 hydrochloride 0.5uM and IGF-11ng / ml) was added to the wells (1ml / wells), and then scraped off the colonies with a cell scraper. Cell aggregates in NEIM medium at 10 cm 2 Grow in low-adsorption Corning dishes for 48 hours. After 48 h, the floating cell aggregates were collected and seeded on Coated plates were cultured in RPEIM (DMEM / F12, KO...

Embodiment 2

[0294] A clinical-grade three-phase protocol efficiently and reproducibly generates AMD-iRPE cells

[0295] iPSCs derived from AMD patient skin fibroblasts acquired chromosomal copy number changes under clinical-grade conditions, likely during reprogramming (Mandai et al., N Engl J Med 376, 1038-1046 (2017)). However, when deriving iPSCs from older patients, skin fibroblasts are not considered an ideal starting source (Kang et al., Cell Stem Cell 18, 625-636 (2016)). Therefore, a production workflow for obtaining autologous iPSC-derived RPE patches from patient CD34+ peripheral blood cells was developed. Development of a pipeline diagram for the generation, functional validation and in vivo testing of clinical-grade AMD patient-specific iPSC-RPE patches ( Figure 1A , B). Due to their progenitor and proliferative properties, CD34+ cells isolated from peripheral blood of patients can provide a good source for iPSC generation. Using a clinical-grade additive genetic reprogram...

Embodiment 3

[0302] Biodegradable scaffold facilitates functional maturation of clinical-grade AMD-iRPE cells into monolayer tissue

[0303] It was hypothesized that a biodegradable scaffold would provide a suitable material for RPE cells to secrete extracellular matrix (ECM) to form polarized monolayers. As the scaffold degrades, the ECM and cells will form a native RPE-like tissue, which will increase the likelihood of long-term integration of the iRPE patch in the patient's eye. Scaffolds used in clinical-grade procedures were produced using poly-(lactic-co-glycolic acid) / PLGA (50:50 lactic / glycolic acid, IV midpoint 1.0 dl / g), The average fiber diameter was previously shown to be 350 nm to be optimal for RPE growth (Liu, et al., Biomaterials 35, 2837-2850 (2014); Stanzel et al., Stem Cell Reports 2, 64-77 (2014)). A single-layer heat-fused nanofibrous scaffold was chosen for iRPE patch production because its high Young's modulus correlates with ease of grafting ( Figure 2A , 2B). A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
pore sizeaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

Tissue replacement implants are disclosed that include polarized retinal pigment epithelial cells on a poly(lactic-co-glycolic acid) (PLGA) scaffold, wherein the PLGA scaffold is 20-30 microns in thickness, has a DL-lactide / glycotide ratio of about 1:1, an average pore size of less than about 1 micron, and a fiber diameter of about 150 to about 650 nm. Also disclosed are methods of treating a subject with a retinal degenerative disease, retinal or retinal pigment epithelium dysfunction, retinal degradation, retinal damage, or loss of retinal pigment epithelium. These methods include locally administering to the eye of the subject the tissue replacement implant. In further embodiments, methods are disclosed for producing the tissue replacement implant.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 769,484, filed November 19, 2018, which is incorporated herein by reference. [0003] Statement of Government Support [0004] This invention was made with government support under Project No. ZA1#: ET000542-03 provided by the National Institutes of Health, National Eye Institute. The government has certain rights in this invention. technical field [0005] The present disclosure relates to the field of cell-based therapies, and in particular to tissue replacement implants comprising retinal pigment epithelial (RPE) cells, and methods of making and using these tissue replacement implants. Background technique [0006] Cell-based therapy promises to "permanently" replace degenerated tissue. The eye is an area of ​​interest because of its accessibility and the urgent need for effective therapies to help the growing population of older adults...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L27/18A61L27/38A61L27/54A61L27/58
CPCA61L27/54A61L27/58A61L27/3813A61L27/3834A61L27/3869A61L27/18A61L2430/16C08L67/04A61L27/56A61F9/0017
Inventor A·马尼尼什基斯K·巴蒂
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap